BSR has published an update to the axial spondyloarthritis guideline.

It's almost 10 years since the last iteration of the guideline. Our understanding and awareness of the disease has increased enormously. We now have 10 different therapies licensed for advanced management of axial spondyloarthritis, which are broadly divided into three different classes: TNF inhibitors, IL17 and JAK inhibitors. 

Join guideline working group Co-Chairs, Karl Gaffney, and Steven Zhao, members William Gregory and Stephanie Harrison, and expert by experience member and CEO of NASS, Dale Webb, in a roundtable discussion hosted by Prof Ernest Choy.

Read the full guideline and download the summary pdf here. 

Thanks for listening to Talking Rheumatology! Join the conversation on X using #TalkingRheum or tweet us @RheumatologyUK.

BSR is the UK's leading specialist medical society for rheumatology and MSK health professionals. To discover how we can support you in delivering the best care for your patients, visit our website.

Id. d’épisode : 1000702832353

GUID : Buzzsprout-16575140

Date de publication : 9/4/2025 à 09:00:00